A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients

Cancer Investigation

Volumn 20, Issue 2, 2002, Pages 186-191

  Oh, William K ^a   Manola, Judith ^a   George, Daniel J ^a   Fierman, Abby ^a   Fontaine Rothe, Pamela ^a   Morrissey, Stephanie ^a   Prisby, Judith ^a   Kaufman, Donald S ^a   Shapiro, Charles L ^b   Kantoff, Philip W ^a   Smith, Matthew R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIESTROGEN; TOREMIFENE;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG POTENTIATION; FATIGUE; FEMALE; HUMAN; KIDNEY CANCER; MALE; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TIME FACTORS; TOREMIFENE;

EID: 18344372378     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120001145     Document Type: Article

References (26)

1. Systemic therapy for renal cell carcinoma
2. Chemotherapy for advanced renal cell carcinoma
3. Immunotherapy for metastatic renal cell carcinoma
4. The interferons: Mechanisms of action and clinical application
5. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma
6. Study of tamoxifen in patients with advanced renal cell carcinoma
7. Study of tamoxifen in metastatic renal cell carcinoma and the influence of certain prognostic factors: A southwest oncology group study
8. Tamoxifen in unresectable hypernephoma: A phase II trial and review of the literature
9. Highdose tamoxifen in metastatic renal cell carcinoma
10. Lonidamine vs. high-dose tamoxifen in progressive advanced renal cell carcinoma: Results of an ongoing randomized phase II study
11. A phase II study of high dose tamoxifen in progressive metastatic renal cell carcinoma
12. Hormonal therapy for metastatic renal cell carcinoma: Combined androgen and provera followed by high dose tamoxifen
13. Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma
14. Survival in renal cell carcinoma - A randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen
15. Randomized comparison of tamoxifen and two doses of toremiphene in postmenopausal patients with metastatic breast cancer
16. High-dose toremifene in advanced renal cell carcinoma
17. Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cell cells (Zr-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen
18. Tamoxifen and beta-interferon: Effect of simultaneous or sequential treatment on breast cancer cell lines
19. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro
20. Additive and synergistic antitumor effects with toremifene and interferons
21. Nonparametric estimation from incomplete observations
22. Phase I study of toremifene in patients with advanced cancer
23. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer
24. Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer
25. Tamoxifen and interferon-beta for the treatment of metastatic breast cancer
26. High dose oral tamoxifen and subcutaneous interferon alpha-2A for recurrent glioma